BioMarin Pharmaceutical Inc.

    Jurisdiction
    United States
    LEI
    NSLL8ITTRR0J5HEMR848
    ISIN
    US09061G1013 (BMRN)
    Sectors
    1. Healthcare
    2. Biotechnology

    Scores

    InsiderPie Expert Score
    64 / 100
    Better than peer group:
    50 / 100
    Fair value (Benjamin Graham formula)
    €97.84 108.2% undervalued
    Financial strength (Piotroski F-Value)
    9 / 9
    Fundamental strength relative to industry (Mohanram G-Value)
    6 / 7

    Profile

    BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Read full profile

    Fundamentals

    Net revenue
    €2.61B
    Gross margin
    79.5%
    EBIT
    €661.96M
    EBIT margin
    25.4%
    Net income
    €560.59M
    Net margin
    21.5%

    Statement period: - (published )

    Estimates

    Fiscal Year Net revenue Net income
    €2.95B +13.3% €765.07M +36.5%
    €3.17B +7.3% €917.88M +20.0%
    €3.34B +5.5% €1.12B +22.4%

    Stock price

    Stock price loading... No stock price available Stock price provided by Lang & Schwarz Steigende Zinsen und niedrigere Bewertungen für Wachstumsaktien im Allgemeinen Eine Gewinnwarnung beim Konkurrenten Adyen signalisiert eine Abkühlung des europäischen Markts für Zahlungsdienstleistungen. Eine Gewinnwarnung von Wordline SA triggert einen massiven Kursverlust.

    Configure chart

    Adjust colors to be more accessible for red-green-colorblind users.
    Scale
    Moving average Display a moving average line on the chart.

    Dividends

    No dividend payouts

    Analyst ratings

    No analyst ratings available

    Insider Transactions

    No insider transactions in the last 90 days. View older insider transactions

    Investor transactions

    Name Shares Value Last change Change type
    Andreas Halvorsen 11M $763.46M +290K Buy
    Peter Brown 896K $63.32M +460K Buy
    Ray Dalio 124K $8.74M -179K Sell

    Earnings Calls

    Add to watchlist

    Notifications